Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines, a clinical-stage oncology company (Nasdaq: RVMD), announced participation in two investor conferences. CEO Mark A. Goldsmith will host fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, 2022, at 7:00 a.m. Eastern, and the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022, with his chat scheduled for December 1 at 2:15 p.m. Eastern. Webcasts of the chats will be available online, with archived replays for at least 14 days.

Revolution Medicines (RVMD) reported its Q3 2022 financial results, highlighting ongoing Phase 1/1b trials for RMC-6236 and RMC-6291, aimed at treating RAS-addicted cancers. The company completed a public equity financing in July, raising approximately $265 million to enhance its financial position. Q3 revenue stood at $3.4 million, with a net loss of $73.3 million. R&D expenses rose to $69.5 million, driven by clinical trial activities. RVMD maintains a cash position of $655 million, projecting to fund operations through 2024.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology firm, will report its third-quarter financial results on November 7, 2022, after market close. The company is focused on developing therapies for RAS-addicted cancers, with RMC-6236 and RMC-6291 currently in clinical trials. Senior management will host a webcast at 4:30 p.m. ET on the same day to discuss the financial outcomes and corporate advancements, which will be accessible via their website for 14 days post-event.

Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the first patient has been dosed in its Phase 1/1b clinical trial of RMC-6291, a novel oral, selective KRAS^G12C(ON) Inhibitor. This trial aims to evaluate the drug's safety and tolerability in patients with advanced solid tumors harboring the KRAS^G12C mutation. RMC-6291 is the first candidate from Revolution's pipeline of mutant-selective RAS(ON) Inhibitors, followed closely by RMC-6236, its RAS^MULTI(ON) Inhibitor. The company believes its complementary approaches will be effective against RAS-addicted cancers.

Revolution Medicines (Nasdaq: RVMD) announced key leadership changes, promoting Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel. Daniel Simon will join as Chief Business Officer. Anders boasts 20 years of finance experience, pivotal in the company's growth into a clinical-stage firm. Cislini brings over 20 years in legal expertise, focusing on governance and compliance. Simon, with 15 years in life sciences, is expected to enhance strategic planning and business development. These appointments aim to strengthen Revolution Medicines' focus on RAS-addicted cancer therapies.

Revolution Medicines, Inc. (Nasdaq: RVMD) announced participation in upcoming investor conferences, with CEO Mark A. Goldsmith set to speak at both events. The 2022 Wells Fargo Healthcare Conference will take place from September 7-9, featuring Goldsmith's fireside chat on September 8 at 3:45 p.m. Eastern. The H.C. Wainwright 24th Annual Global Investment Conference follows from September 12-14, with a chat scheduled for September 12 at 7:00 a.m. Eastern. A webcast of the latter will be available online for 14 days post-event.

Revolution Medicines (Nasdaq: RVMD) reported Q2 2022 financial results and significant progress in its clinical development pipeline targeting RAS-addicted cancers. The company commenced patient dosing in its Phase 1/1b trials for RMC-6236 and RMC-6291, advancing its RAS(ON) Inhibitor portfolio. They raised $265 million through public equity financing to support these developments. Notably, total revenue increased to $9.1 million, while net loss widened to $61.2 million. The company projected a net loss of $260 to $280 million for 2022, but affirmed sufficient funds to operate through 2024.

Revolution Medicines (Nasdaq: RVMD) will announce its Q2 2022 financial results on August 9, 2022, post-market close. A conference call led by the senior management team is scheduled for 4:30 p.m. ET to discuss the results and corporate progress. The company focuses on RAS-addicted cancers with a diverse pipeline of RAS(ON) Inhibitors, including RMC-6236 and RMC-6291, among others. The live conference can be accessed via a dedicated webcast.

Revolution Medicines has successfully completed a public offering of 13,225,000 shares of common stock at $20.00 per share, raising gross proceeds of $264.5 million. This includes the full exercise of an underwriters' option for an additional 1,725,000 shares. The offering, which is targeted at advancing the company’s oncology pipeline, was managed by J.P. Morgan, Cowen, and Guggenheim Securities. This offering follows a shelf registration statement filed with the SEC in March 2021.